Trump administration ends Medicare drug plan subsidies, raising cost concerns ahead of midterms
The White House announced that subsidies for private Medicare prescription drug plans will be discontinued, a move expected to increase premiums for many seniors.
The policy shift comes as Democrats intensify criticism of Republican health-care policies ahead of the upcoming midterm elections, framing the change as a burden on older Americans.
Senate Minority Leader Chuck Schumer described the decision as heartless and cruel, arguing it will exacerbate out-of-pocket costs for beneficiaries.
The termination of the subsidy could affect the market for Medicare-advantaged plans and may influence pharmaceutical pricing strategies and investor outlooks.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: End of Medicare drug subsidy gives Democrats new attack line on rising out-of-pocket costs”
read at STAT ↗
comments(0)
5-min edit window · permanent after that